Winston Pharmaceuticals

Winston Pharmaceuticals FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Winston Pharmaceuticals (WPHM) as of Oct 30, 2026 is 158.15 %.

FCF Conversion

158.15 %

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Winston Pharmaceuticals is 2009 158.15 % . FCF Conversion Rate (FCF/EBITDA) of Winston Pharmaceuticals was 2008 - . It decreases by % lower compared to the previous year.

The Winston Pharmaceuticals FCF Conversion history

The Winston Pharmaceuticals FCF Conversion history
YEARFCF ConversionYoY
158.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Winston Pharmaceuticals Stock analysis

What does Winston Pharmaceuticals do? Winston Pharmaceuticals Inc is a pharmaceutical company based in the USA, focused on drug development and marketing. The company was founded in 1999 and has since built a successful history in the industry. The business model of Winston Pharmaceuticals is to develop and market innovative drugs that enable sustainable improvement in the health and quality of life of patients. The company invests in research and development, as well as clinical testing of its products, to ensure effectiveness and safety. Winston Pharmaceuticals is divided into various divisions, including oncology, cardiovascular, and neuropsychiatric disorders. Each division focuses on specific areas of disease to allow for targeted and focused research and development strategies. In the oncology division, Winston Pharmaceuticals focuses on developing drugs for the treatment of cancer types such as breast, prostate, and lung cancer. The company has a range of products in different stages of development, including the emerging cancer drug candidate WPH-333. In the cardiovascular division, Winston Pharmaceuticals has developed a range of drugs that can be used to treat conditions such as hypertension, angina, heart failure, and thromboembolism. The company also focuses on researching the pathophysiology of cardiovascular diseases to develop new therapeutics. In the neuropsychiatric division, Winston Pharmaceuticals develops drugs for the treatment of disorders such as schizophrenia, depression, and anxiety. The company is also involved in the development of novel drugs for the treatment of brain injuries and diseases such as Alzheimer's. Some of Winston Pharmaceuticals' most well-known products include Insidon, an antidepressant, Limbitrol, a medication for the treatment of depression, and Wolfsbane, a calming antipsychotic. The company has also recently launched the medication WPH-231 for the treatment of schizophrenia. In terms of regulatory affairs, Winston Pharmaceuticals works closely with regulatory authorities to ensure compliance with all regulations and approval requirements. The company places great emphasis on quality and safety, ensuring that all products meet the highest industry standards. Winston Pharmaceuticals has made a name for itself in the industry due to its extensive experience, top-notch research team, and innovative capabilities. The company aims to provide patients worldwide with the best drugs while maintaining responsible and sustainable business practices. Overall, Winston Pharmaceuticals is an emerging company in the pharmaceutical industry that will produce many promising products due to its extensive research and development activities and focus on targeted disease areas. Winston Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Winston Pharmaceuticals stock

FCF Conversion Rate (FCF/EBITDA) of Winston Pharmaceuticals is 158.15 % in 2009.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Winston Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Winston Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Winston Pharmaceuticals

All Key Metrics — Winston Pharmaceuticals